Researchers tested the new GLP-1 pill orforglipron in a global phase 3 trial.
Adults with type 2 diabetes lost more weight than with oral semaglutide.
Average loss reached six to eight percent of body weight after one year.
The drug lowers blood sugar and reduces appetite without fasting before use.
Participants also achieved better glucose control at both tested doses.
About ten percent stopped treatment because of gastrointestinal side effects.
Fewer patients discontinued semaglutide.
Regulators still review the medication in major markets.
Experts expect oral GLP-1 therapies to expand access because tablets simplify storage and use.
Researchers now need longer studies to confirm safety and cardiovascular benefits.
Many specialists see these drugs as future first-line treatments for type 2 diabetes.
